Effects of Anagrelide on Megakaryopoiesis and Platelet Production

ABSTRACT

Possible pathomechanisms regarding the thromboreductive effect of anagrelide (ANA) include decrease in the megakaryocyte cell mass or life span of platelets, interference with maturation, and stimulation of apoptosis and proliferation. Finally, a fibrogenic effect has been reported in patients with high-risk essential thrombocythemia (ET). Based on scrutinized evaluations, including immunohistochemistry and morphometry performed on representative bone marrow (BM) biopsies, ANA was found to exert a significant influence on the endoreduplicative activity of megakaryopoiesis, with an arrest of maturation at lower ploidy stages causing a predominance of precursors. This result confirms and greatly extends former investigations that also failed to document a decrease in quantity or enhancement of apoptosis. Moreover, a comparative study on the putative mutagenic capacity of hydroxyurea (HU) versus ANA treatment reveals that both agents generate a left-shifting of megakaryocytes. However, HU creates conspicuously expressed maturation defects consistent with dysplastic changes of megakaryopoiesis, and therefore supports concerns about the possible leukemogenic potential of this drug. On the other hand, in follow-up examinations of BM specimens, ANA failed to show a stimulation of myelofibrosis in ET, provided diagnosis was established according to the World Health Organization criteria.

KEYWORDS

Megakaryocytes - endoreduplicative capacity - apoptosis - proliferation - anagrelide - hydroxyurea - maturation defects - fibrogenic activity

REFERENCES

• 1 Schafer A I. Thrombocytosis.  N Engl J Med. 2004;  350 1211-1219
• 2 Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management.  Blood Rev. 2001;  15 121-131
• 3 Barbui T, Finazzi G. Risk factors and prevention of vascular complications in polycythemia vera.  Semin Thromb Hemost. 1997;  23 455-461
• 4 Barbui T. Indications for lowering platelet numbers in essential thrombocythemia.  Semin Hematol. 2003;  40 22-25
• 5 Barbui T, Finazzi G. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.  Curr Hematol Rep. 2003;  2 248-256
• 6 Griesshammer M, Langer C. Pharmacotherapy of essential thrombocythaemia: economic considerations.  Expert Opin Pharmacother. 2003;  4 1499-1505
• 7 Pescatore S L, Lindley C. Anagrelide: a novel agent for the treatment of myeloproliferative disorders.  Expert Opin Pharmacother. 2000;  1 537-546
• 8 Tefferi A, Silverstein M N, Petitt R M, Mesa R A, Solberg Jr L A. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.  Semin Thromb Hemost. 1997;  23 379-383
• 9 Tefferi A, Elliott M A, Solberg Jr L A, Silverstein M N. New drugs in essential thrombocythemia and polycythemia vera.  Blood Rev. 1997;  11 1-7
• 10 Silverstein M N, Petitt R M, Solberg Jr L A, Fleming J S, Knight R C, Schacter L P. Anagrelide: a new drug for treating thrombocytosis.  N Engl J Med. 1988;  318 1292-1294
• 11 Balduini C L, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.  Haematologica. 1992;  77 40-43
• 12 Mazzucconi M G, De Sanctis V, Chistolini A, Dragoni F, Mandelli F. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results.  Haematologica. 1992;  77 315-317
• 13 Petrides P E, Beykirch M K, Trapp O M. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany.  Eur J Haematol. 1998;  61 71-76
• 14 Bellucci S, Legrand C, Boval B, Drouet L, Caen J. Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with anagrelide.  Br J Haematol. 1999;  104 886-892
• 15 Silverstein M N, Tefferi A. Treatment of essential thrombocythemia with anagrelide.  Semin Hematol. 1999;  36 23-25
• 16 Laguna M S, Kornblihtt L I, Marta R F, Michiels J J, Molinas F C. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia.  Clin Appl Thromb Hemost. 2000;  6 157-161
• 17 Anagrelide Study Group . Anagrelide, a therapy for thrombocythemic states: experience in 577 patients.  Am J Med. 1992;  92 69-76
• 18 Petitt R M, Silverstein M N, Petrone M E. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders.  Semin Hematol. 1997;  34 51-54
• 19 Andersson B S. Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide.  Hematology (Am Soc Hematol Educ Program). 2002;  7 173-177
• 20 Solberg Jr L A. Therapeutic options for essential thrombocythemia and polycythemia vera.  Semin Oncol. 2002;  29 10-15
• 21 Storen E C, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia.  Blood. 2001;  97 863-866
• 22 Brooks W G, Stanley D D, Goode J V. Role of anagrelide in the treatment of thrombocytosis.  Ann Pharmacother. 1999;  33 1116-1118, 1121
• 23 Petrides P E. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.  Expert Opin Pharmacother. 2004;  5 1781-1798
• 24 Dingli D, Tefferi A. A critical review of anagrelide therapy in essential thrombocythemia and related disorders.  Leuk Lymphoma. 2005;  46 641-650
• 25 Liozon E, Brigaudeau C, Trimoreau F et al.. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature.  Hematol Cell Ther. 1997;  39 11-18
• 26 Sterkers Y, Preudhomme C, Lai J L et al.. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.  Blood. 1998;  91 616-622
• 27 Finazzi G, Barbui T. Treatment of essential thrombocythemia with special emphasis on leukemogenic risk.  Ann Hematol. 1999;  78 389-392
• 28 Randi M L, Fabris F, Girolami A. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.  Leuk Lymphoma. 2000;  37 379-385
• 29 Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?.  Semin Hematol. 2004;  41 15-17
• 30 Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.  Br J Haematol. 2000;  110 577-583
• 31 Fruchtman S M. Treatment paradigms in the management of myeloproliferative disorders.  Semin Hematol. 2004;  41 18-22
• 32 Furgerson J L, Vukelja S J, Baker W J, O'Rourke T J. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.  Am J Hematol. 1996;  51 137-140
• 33 Higuchi T, Okada S, Mori H, Niikura H, Omine M, Terada H. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent.  Cancer. 1995;  75 471-477
• 34 Löfvenberg E, Nordenson I, Wahlin A. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease.  Cancer Genet Cytogenet. 1990;  49 57-67
• 35 Nielsen I, Hasselbalch H C. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.  Am J Hematol. 2003;  74 26-31
• 36 Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.  Eur J Haematol. 1994;  52 134-139
• 37 Abe Andes W, Noveck R J, Fleming J S. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers.  Thromb Haemost. 1984;  52 325-328
• 38 Mazur E M, Rosmarin A G, Sohl P A, Newton J L, Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans.  Blood. 1992;  79 1931-1937
• 39 Solberg Jr L A, Tefferi A, Oles K J et al.. The effects of anagrelide on human megakaryocytopoiesis.  Br J Haematol. 1997;  99 174-180
• 40 Le Bousse-Kerdiles M C, Martyre M C. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.  Ann Hematol. 1999;  78 437-444
• 41 Martyre M C. Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia.  Curr Hematol Rep. 2003;  2 257-263
• 42 Schmitt A, Drouin A, Masse J M, Guichard J, Shagraoui H, Cramer E M. Polymorphonuclear neutrophil and megakaryocyte mutual involvement in myelofibrosis pathogenesis.  Leuk Lymphoma. 2002;  43 719-724
• 43 Harrison C N, Campbell P J, Buck G et al.. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.  N Engl J Med. 2005;  353 33-45
• 44 Yoon S Y, Li C Y, Mesa R A, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia.  Br J Haematol. 1999;  106 682-688
• 45 Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia.  Blood. 2002;  99 1602-1609
• 46 Tomer A, Friese P, Conklin R et al.. Flow cytometric analysis of megakaryocytes from patients with abnormal platelet counts.  Blood. 1989;  74 594-601
• 47 Gatter K C, Cordell J L, Turley H et al.. The immunohistological detection of platelets, megakaryocytes and thrombi in routinely processed specimens.  Histopathology. 1988;  13 257-267
• 48 Thiele J, Wagner S, Dienemann D, Wienhold S, Fischer R, Stein H. Megakaryocyte precursors (promegakaryoblasts and megakaryoblasts) in the normal human bone marrow. An immunohistochemical and morphometric study on routinely processed trephine biopsies.  Anal Quant Cytol Histol. 1990;  12 285-289
• 49 Thiele J, Wagner S, Degel C et al.. Megakaryocyte precursors (pro- and megakaryoblasts) in bone marrow tissue from patients with reactive thrombocytosis, polycythemia vera and primary (essential) thrombocythemia. An immunomorphometric study.  Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;  58 295-302
• 50 Ishibashi T, Ruggeri Z M, Harker L A, Burstein S A. Separation of human megakaryocytes by state of differentiation on continuous gradients of Percoll: size and ploidy analysis of cells identified by monoclonal antibody to glycoprotein IIb/IIIa.  Blood. 1986;  67 1286-1292
• 51 Levene R B, Williams N T, Lamaziere J M, Rabellino E M. Human megakaryocytes. IV. Growth and characterization of clonable megakaryocyte progenitors in agar.  Exp Hematol. 1987;  15 181-189
• 52 Levine R F, Hazzard K C, Lamberg J D. The significance of megakaryocyte size.  Blood. 1982;  60 1122-1131
• 53 Williams N, Levine R F. The origin, development and regulation of megakaryocytes.  Br J Haematol. 1982;  52 173-180
• 54 Queisser U, Queisser W, Spiertz B. Polyploidization of megakaryocytes in normal humans, in patients with idiopathic thrombocytopenia and with pernicious anaemia.  Br J Haematol. 1971;  20 489-501
• 55 Thiele J, Kvasnicka H M, Fuchs N, Brunnbauer K, Volkwein N, Schmitt-Graeff A. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies.  Haematologica. 2003;  88 1130-1138
• 56 Hall P A, Levison D A. Review: assessment of cell proliferation in histological material.  J Clin Pathol. 1990;  43 184-192
• 57 Thiele J, Kvasnicka H M, Ollig S, Schmitt-Graeff A. Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis-a comparative immunohistochemical and morphometric study with hydroxyurea.  Histol Histopathol. 2005;  20 1071-1076
• 58 Tricot G, De Wolf-Peeters C, Hendrickx B, Verwilghen R L. Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears.  Br J Haematol. 1984;  57 423-430
• 59 Delacretaz F, Schmidt P M, Piguet D, Bachmann F, Costa J. Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy.  Am J Clin Pathol. 1987;  87 180-186
• 60 Fox S B, Lorenzen J, Heryet A, Jones M, Gatter K C, Mason D Y. Megakaryocytes in myelodysplasia: an immunohistochemical study on bone marrow trephines.  Histopathology. 1990;  17 69-74
• 61 Rios A, Canizo M C, Sanz M A et al.. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors.  Br J Haematol. 1990;  75 26-33
• 62 Thiele J, Imbert M, Pierre R. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissue. Lyon, France; IARC Press 2001: 35-38
• 63 Thiele J, Wagner S, Weuste R et al.. An immunomorphometric study on megakaryocyte precursor cells in bone marrow tissue from patients with chronic myeloid leukemia (CML).  Eur J Haematol. 1990;  44 63-70
• 64 Thiele J, Kvasnicka H M, Schmitt-Graeff A, Diehl V. Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis.  Histopathology. 2003;  43 470-479
• 65 Harrison C N. Essential thrombocythemia: challenges and evidence-based management.  Br J Haematol. 2005;  130 153-165
• 66 Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia.  Semin Hematol. 1999;  36 9-13
• 67 Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.  Semin Hematol. 1997;  34 29-39
• 68 Pearson T C. Diagnosis and classification of erythrocytoses and thrombocytoses.  Baillieres Clin Haematol. 1998;  11 695-720
• 69 Florena A M, Tripodo C, Iannitto E, Porcasi R, Ingrao S, Franco V. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia.  Haematologica. 2004;  89 911-919
• 70 Thiele J, Kvasnicka H M, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.  Haematologica. 2000;  85 1126-1134
• 71 Thiele J, Kvasnicka H M. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.  Ann Hematol. 2003;  82 148-152
• 72 Imbert M, Pierre R, Thiele J, Vardiman J W, Brunning R D, Flandrin G. Essential thrombocythaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France; IARC Press 2001: 39-41
• 73 Buhr T, Busche G, Choritz H, Langer F, Kreipe H. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.  Am J Clin Pathol. 2003;  119 152-158
• 74 Georgii A, Buesche G, Kreft A. The histopathology of chronic myeloproliferative diseases.  Baillieres Clin Haematol. 1998;  11 721-749
• 75 Thiele J, Kvasnicka H M, Schmitt-Graeff A, Diehl V. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients.  Leuk Lymphoma. 2003;  44 949-953
• 76 Thiele J, Kvasnicka H M. Prefibrotic chronic idiopathic myelofibrosis-a diagnostic enigma?.  Acta Haematol. 2004;  111 155-159
• 77 Kreft A, Buche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick C J. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.  Acta Haematol. 2005;  113 137-143
• 78 Thiele J, Kvasnicka H M, Dietrich H et al.. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation.  Histol Histopathol. 2005;  20 879-889
• 79 Thiele J, Kvasnicka H M. Clinicopathological criteria for differential diagnosis of thrombocythemias in various MPDs.  Semin Thromb Hemost. 2006;  32 219-230
• 80 Kvasnicka H M, Thiele J. The impact of clinicopathological studies in staging and survival in ET, PV and IMF.  Semin Thromb Hemost. 2006;  32 362-371
• 81 Thiele J, Kvasnicka H M, Orazi A. Bone marrow histopathology in myeloproliferative disorders-current diagnostic approach.  Semin Hematol. 2005;  42 184-195